Area of research
Hematology · Genetics
Research interest
Research interests include Acute Myeloid Leukemia Research, Chronic Myeloid Leukemia Treatments, Chronic Lymphocytic Leukemia Research, and Platelet Disorders and Treatments.
Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3–internal tandem duplications in the QuANTUM-First trial
<i>FLT3</i> -ITD measurable residual disease from the QuANTUM-First trial
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) <i>FLT3</i>-ITD+ AML Patients (pts)
P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL
Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD) Positive Acute Myeloid Leukemia (AML)
CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition With Quizartinib in Acute Myeloid Leukemia (AML) With FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Oral Abstract: CT-186 Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in First Complete Remission (CR1) in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia (AML) with FLT3–Internal Tandem Duplication (FLT3-ITD): Results from the QuANTUM-First Trial
Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First
Quantum-First Trial: <i>FLT3</i>-ITD-Specific MRD Clearance Is Associated with Improved Overall Survival
Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with <i>FLT3</i>-Internal Tandem Duplication: Results from the Quantum-First Trial